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Phototherapy has still great importance in the treatment of atopic dermatitis, though costs, compliance, and long-term risks
narrow its relevance. In spite of its long history, up to now, the therapeutic regimes are mostly empirical. Narrowband UVB und
UVA1 are the most frequently applied regimens in atopic dermatitis with proven eﬃcacy. However, even for these modalities
randomized prospective and controlled studies are still pending. Advances in photoimmunology and molecular biology had
demonstrated that phototherapy targets inﬂammatory cells, alters cytokine production, and has a signiﬁcant antimicrobial eﬀect
within atopic skin. This paper summarizes the current literature on the diﬀerent regimes of phototherapy and also discusses
therapeutic modalities like photochemotherapy and extracorporeal photopheresis. These more complex regimes should be
restricted to severe cases of atopic dermatitis, which are refractory to topical treatment.
1.Introduction
Atopic dermatitis is a common chronic relapsing inﬂamma-
tory skin disease, which aﬀects patients of all life decades.
Therapy of atopic dermatitis is mainly based on topical ther-
apies like moisturizers, corticosteroids, or calcineurin inhibi-
tors and avoidance of trigger factors. Systemic anti-inﬂam-
matory treatment remains an option in severe cases. Though
ab e n e ﬁ c i a le ﬀect of solar exposure has been appreciated for
decades, phototherapy of atopic dermatitis has been largely
empirical. Since the early twenties it was known that sea cli-
mate can improve atopic dermatitis and soon it was addi-
tionally recognized that atopic dermatitis improved during
the summer season. In 1948, the helpful eﬀects of UV radia-
tion were studied for the ﬁrst time by exposing patients to
radiationemittedfromcarbonarclamps[1].Fromthe1970s





like psoriasis. In general, phototherapy is indicated in chro-
nic stages of atopic dermatitis, except UVA1 which is also
eﬀective in acute ﬂares [2]. However, phototherapy has to
b eap a r to fac o m p r e h e n s i v et r e a t m e n tp l a n ,w h i c hh a st o
consider some limitations. UV therapy requires special tech-
nical equipment and trained staﬀ. Furthermore, patients
have to be compliant to follow a therapy plan for 3–5 times
a week up to 6–12 weeks. Some areas like hairy skin and skin
folds are diﬃcult to treat, which limits the eﬃciency. The
advances in photoimmunology and molecular biology give
explanation to the mode of action of diﬀerent photother-
apeutic regimes. Phototherapy targets inﬂammatory cells,
alterscytokineproductionsandhasasigniﬁcantantibacterial
eﬀect. Nevertheless, the majority of concepts in photother-
apy of atopic dermatitis are still empirical today. The lack of
randomized controlled trials, which compare the diﬀerent
phototherapeutic regimens, still limits recommendations for
the most appropriate phototherapeutic regimen. This paper
deals with the main present modalities of UV therapy.
Searches on phototherapy and atopic dermatitis were per-
formed using Pubmed and cross-references of these publica-
tions.
2. UVB Phototherapy
2.1. Broadband UVB. UVB phototherapy (290–320nm), as
the “oldest” phototherapeutic regimen, has a long tradition
in treating atopic dermatitis and started with the exposure of2 Journal of Allergy
patients to carbon arc lamps. UVB ﬂuorescent and mercury
arc lamps made UVB regimens the therapy of choice for
quite a long time and its eﬃcacy was documented in several
studies [3–5]. In one of the ﬁrst studies, atopic patients (n =
17) were irradiated with broadband UVB (0.5–1.0 minimal
erythema dose, MED) compared with visible light (each re-
gimen applied to one-half of the body over 8 weeks). This led
inthemajorityofpatientstoacompletehealingofthelesions
compared to visible-light-exposed areas. The same group ex-
amined also the therapeutic dose response to UVB (0.8 MED
versus 0.4 MED applied to one-half of the body) for eight
weeks (n = 24). However, although both UVB doses were
found to be eﬀective, no signiﬁcant diﬀerences were found
between the doses applied. This supports the fact that lower
doses are equally eﬀective compared with near erythemo-
genic doses [3]. In another study in 107 atopic patients, UVB
was applied once daily for 4–19 days. A beneﬁcial eﬀect was
observed in 93% of the cases as well as a signiﬁcant corti-
costeroid-sparing eﬀect [6]. However, the used irradiation
device (Psorilux 9050) emitted also to a certain extend in the
UVArangewhenlookingatthereportedemissionspectra.In
psoriasis, which is still the most frequent indication for UVB
therapy, the comparison of the therapeutic spectra showed
the highest eﬃcacy in the range of around 313nm [7, 8].
Subsequently, a narrowband (311–313nm) UVB ﬂuorescent
lamp (Philips TL01) was introduced [9].
2.2. Narrowband UVB. N a r r o w b a n dU V Bi sm u c hl e s se r y -
themogenic due to the exclusion of short wave lengthUVB
irradiation. Data comparing the carcinogenic risks of nar-
rowband UVB and broadband UVB are limited in humans
[10]. In 2004, the skin cancer risk in 195 psoriasis patients
treated with broadband or narrowband UVB phototherapy
was surveyed retrospectively and did not provide evidence
forasigniﬁcantincreasedskincancerriskduringanobserva-
tion period of ten years [11]. However, prospective longitu-
dinal studies with prolonged follow-up periods are required.
In a large cohort (n = 1908) a median number of 23 treat-
ments did not result in an increased incidence of squamous
cell carcinoma or melanoma (median followup 4 (0.04–13)
years), though the risk of basal cell carcinoma was increased
twofold. However, to determine the deﬁnite risk, deﬁnitely
longer followup is essential as well [12]. Based on the human
carcinogenesis action spectrum, the carcinogenic risk of nar-
rowband UVB lamps is estimated 50% higher for equal ery-
themal doses than selected broadband lamps. An epidemi-
ologic evidence is still pending [13], while in mice, narrow-
band UVB irradiation produced more malignant skin tu-
mors [14]. Nevertheless, narrowband UVB is more eﬀective
in treating psoriasis and fewer treatments are needed to
achieve remission, which might overall weigh up the higher
carcinogenic risk by less exposure. In psoriasis, narrowband
UVB is superior and has almost entirely replaced broadband
UVB, which led to other indications including atopic derma-
titis [15–20]. Several studies clearly demonstrate the eﬀec-
tiveness of narrowband UVB for treatment of atopic der-
matitis and furthermore show that long-term beneﬁt can
be achieved by phototherapy. Due to worsening of itch and
sweating especially during UVA/UVA-1 therapy, patients
have been treated with air-conditioned narrowband UVB
phototherapy three times weekly for 12 weeks (n = 21),
which resulted in a 68% reduction in atopic dermatitis sever-
ity scores and a concomitant 88% reduction in topical cor-
ticosteoird use [17]. Even after six months 15 patients in this
open study had long-term beneﬁt. The activity of atopic der-
matitiswasmarkedlyreducedafterthreeweeksofirradiation
with a cumulative dose of 9J/cm2 narrowband UVB [18].
The eﬀect of narrowband UVB has been also evaluated in
children. The response wasgood to excellentin 80% (n = 40,
mean age 11 years) whereas the most frequent adverse eﬀects
were erythema and xerosis [15, 20]. Jury et al. reported that
68% of children achieved minimal residual diseases after
treatment (n = 2 5 ) .H o w e v e r ,i tw a sn o tc o m m e n t e do nt h e
eczemaseverity,lengthofremission,orwhethertopicaltreat-
ment was continued during treatment with narrowband
UVB[21].Asix-yearretrospectivestudy(1999–2005)ofnar-
rowband UVB phototherapy for children with atopic derma-
titis (n = 50) achieved in 40% of these patients severe ec-
zema clearance or minimal residual activity; median length
of remission was three months [22]. These patients were per-
mitted to use topical steroids, so it is diﬃcult to assess the
eﬀect of narrowband UVB alone. Recent studies conﬁrmed
narrowband UVB to be an eﬀective and well-tolerated treat-
ment modality in children [23, 24]. In conclusion, UVB
311nm can be successfully used for the phototherapy for
children with atopic dermatitis. Nevertheless, based on the
potential long-term adverse events it should not be regarded
as ﬁrst-line treatment [25]. Since diﬀerent forms of pho-
totherapy including 8-methoxypsoralen bath-PUVA [pso-
ralen plus UVA (PUVA)] are empirically eﬃcient in atopic
patients,itisimportanttocomparethemsystematically.Nar-
rowband UVB was compared to PUVA (each applied on the
half of the body) in patients with severe atopic dermatitis
(n = 12, three times weekly for six weeks). After cessation of
phototherapy, a decrease in the mean baseline SCORAD
score by 64% (PUVA) and 66% (narrowband UVB) was ob-
served[17].Hence,bothregimensappeartobeequallyeﬀec-
tive in atopic dermatitis. No acute severe adverse eﬀects were
reported. In a more recent randomized controlled trial
narrowband UVB (n = 26), broadband UVA (n = 24), and
visible light (n = 23) phototherapy has been applied twice
weekly for 12 weeks. Narrowband UVB was demonstrated to
be very eﬀective in moderate-to-severe adult atopic dermat-
itisandremissionlastedthreemonths.Onlymoderateeﬀects
werenotedforbroadbandUVAphototherapy[19].However,
this study did not demonstrate a signiﬁcant corticosteroid-
sparing eﬀect by either irradiation regimens as has been re-
ported before [17]. A therapy of oral short-term cyclosporin
A for 4 weeks, followed by a washout phase of 4–6 weeks and
consecutive narrowband UVB phototherapy (3 times/week,
upto2months)hasbeenreportedtobeeﬀectiveinthetreat-
ment of severe atopic dermatitis [26]. However, long-term
eﬀects of this protocol has to be viewed very critically especi-
ally regarding its carcinogenic potential. A small trial by
Legat et al. compared narrowband UVB to medium-dose
UVA1 via half-side comparison in nine patients with chronic
atopic dermatitis and conﬁrmed the eﬀect of narrowbandJournal of Allergy 3
UVB.A40%reductionofclinicalseverityscore(Costascore)
under treatment with narrowband UVB and a better reduc-
tionofprurituswasdocumentedwhiletreatmentwithUVA1
did not achieve any statistically signiﬁcant disease reduction
[27]. However, more recent trials demonstrated narrowband
UVB and medium-dose UVA1 to be equally eﬀective in the
treatment of moderate-to-severe atopic dermatitis [28, 29].
2.3. UVA/B Phototherapy. Combination phototherapy of
UVA and UVB irradiations has quite a long history in ato-
piceczema[4,30,31].Itcanbeappliedbyusingspecialtubes
whose emission spectrum includes both ranges (e.g., Metec
Helarium) or by combining UVA and UVB tubes simultan-
eously or in a subsequent manner. UVA/B therapy was pre-
ferentially used since UVA/B could be demonstrated to be
superior to conventional broadband UVB in atopic dermati-
tis. Altogether in 48% of patients a complete remission was
achieved with UVA/B phototherapy (n = 23) compared to
only 27% in patients with UVB (n = 33) with an average of
5 irradiations per week over 4 weeks [32]. These results were
conﬁrmed by a later report. In 30 patients, a combination
of UVA and UVB on one side of the body and UVB on the
other was applied 3 times/week for a total of eight weeks. In
this clinical evaluation, UVA/B treatment was reported to be
superior for all scores including the pruritus score [4]. How-
ever, regarding the extent of the disease, no statistically sig-
niﬁcant diﬀerences were notable. A disadvantage of the com-
bined irradiation is that it is impossible to dose UVA and
UVBseparately.IndeviceswhichareequippedwithUVAand
UVB tubes, both spectra can be dosed individually. UVA/B
therapy was popular, because of its superiority to broadband
UVB.SincetheintroductionofnarrowbandUVBandUVA1,
UVAB therapy has lost some of its importance but is still in
use. In children, a combination of UVB and UVA for ato-
pic dermatitis resulted in 68.3% of the patients in a >70% re-
duction of the SCORAD index [31]. In adult patients with
atopic dermatitis, an ongoing topical therapy with corticos-
teroids resulted in signiﬁcant clinical improvement. Topical
corticosteroids reduced the total UVB dose required and the
duration of treatment without any overall diﬀerence on
remission or side eﬀects compared with UVA/UVB mono-
therapy [33].
2.4. UVA(-1) Phototherapy. In contrast to UVA/B, pure UVA
therapy plays a rather minor therapeutic role. Conventional
UVA ﬂuorescent tubes have only a limited output and thus
require relatively long exposure times to achieve biologically
eﬀective doses. UVA-1 devices, which cover the long wave
length range from 340 to 400nm, emit rather high doses in
a reasonable amount of time [34–39]. The rationale for de-
veloping UVA-1 lamps was the assumption to reduce the
adverse eﬀects by omitting the UVA-2 part (320–340nm),
which is closer to the UVB range. Initially, these high power
UVA-1 lamps were used to perform photoprovocations, con-
secutively, these lamps were also used for therapeutic pur-
poses,becausehighdosesofUVA-1couldbeappliedwithout
inducing, sunburn reaction. It has been reported to be bene-
ﬁcial for patients with acute and recalcitrant atopic eczema
[36, 37, 40, 41]. UVA-1 penetrates deeper into the skin than
UVB and UVA-2, thus, higher doses can reach the dermis,
and the superﬁcial blood vessel plexus and cause biological
eﬀects[42,43].IntheﬁrstpilotstudyofUVA-1irradiationin
atopic dermatitis, a single dose of 130J/cm2 was given for 15
consecutive days [36].Thistreatmentregimenwascompared
to UVA/B irradiation (starting doses 30mJ/cm2 UVB and
7J/cm 2 UVA, resp.). UVA-1 was signiﬁcantly more eﬀective
compared to UVA/B therapy, as well in clinical scores and
in the downregulation of eosinophilic cationic protein levels
[44]. It was quite surprising and unexpected that all patients
responded to UVA-1 therapy after only six exposures [37].
Several years later, a multicenter follow-up study with more
patients revealed that UVA-1 high-dose therapy was superior
incomparisonwithtopicalcorticosteroidsandUVA/Bthera-
py [37]. However, the initially reported quick response of the
previous study could not be reproduced [35]. UVA-1 high
dose therapy is a valuable therapeutic option especially in
acute severe atopic dermatitis but is by far not the standard
treatment as it was promoted after the initial pilot study.
Unfortunately,highpowerUVA-1devicesdevelopheatwhen
applying these high doses and many atopic patients do not
tolerate this. This led to the development of UVA-1 lamps,
which ﬁltered the infrared part, so-called “UVA-1 cold light”.
The eﬃcacy of this regimen was shown in a variety of stud-
ies. A medium-dose UVA-1 cold light (50J/cm2/day for 15
days) induced a signiﬁcant reduction of the SCORAD score
and cytokine receptor levels in atopic eczema [39]. The clini-
caleﬀectwasstillpresentafteraone-monthfollow-up.How-
ever,afterathree-monthfollowuparecurrenceofsymptoms
could be noted [34]. These regimens gave rise to quite con-
troversial opinions about extremely high doses, as medium-
dose UVA-1 regimen was shown to be also of therapeutic
beneﬁt [34, 39]. As a consequence, a comparison of high-
doseversusmedium-doseUVA-1irradiationwasinitiated.In
a half-side comparison by Tzaneva et al. high-dose UVA-1 ir-
radiation (130J/cm2/day for 15 days) led to a 35%, medium-
dose UVA-1 (65J/cm2/day for 15 days) to a 28% decrease in
the SCORAD score [38]. In another study, patients were ran-
domized to receive either low-dose (20J/cm2), medium-dose
(65J/cm2), or high-dose (130J/cm2) UVA-1 [35]. It was
found that the medium-dose and high-dose treatment regi-
mens were superior as compared to the low-dose UVA-1
treated group of patients. However, there were no signiﬁcant
diﬀerences between the high-dose and the medium-dose
groups and the tolerability was higher in the medium-dose
group,whichsupportstheconceptthatmedium-doseUVA-1
is comparatively as eﬀective as exposure to high-doses of
UVA-1 for the treatment of patients with severe generalized
atopic dermatitis. A medium dose of UVA-1 cold light
(45J/cm2 ﬁve times weekly for 4 weeks) showed prolonged
therapeuticallyeﬀectsconcerningdisease activity andquality
of life [45]. However, until now, no state-of-the-art regi-
men could be designed relating to the optimal dose and the
duration and frequency of the treatment. As long as control-
led studies with large numbers of patients are lacking, prefer-
ence should be given to medium-dose regimes. Partial body
UVA-1 phototherapy is an option for localized and deﬁned
areas, which is proven to be successful in the treatment of4 Journal of Allergy
dyshidrotic eczema of the palms and soles. In atopic der-
matitis, medium-dose UVA-1 phototherapy induced in 10
outof12patientshealingofthelesions(15irradiationcycles)
and no relapse occurred up to 3 months [46]. Therefore,
localUVA-1treatmentappearstobeanalternativeoptionfor
the treatment of chronic dermatitis, however, comparative
studies against other phototherapies including photochemo-
therapy are rarely reported [47].
One of the major mechanisms of UVA-1 is T lymphocyte
apoptosis, as demonstrated by in vitro studies. CD4+ T cells
are found in atopic lesions and these T cells undergo apop-
tosisuponUVA-1exposureasdemonstratedinsitu[43].The
appearance of apoptotic T cells was followed by their deple-
tion from cutaneous lesions, a reduction in the in situ ex-
pression of IFN-gamma by T cells and clearing of the atopic
inﬂammation. Furthermore, UVA-1 is also able to modulate
thebalancebetweentheantiapoptotic proteins aspotent reg-
ulators of T-cell apoptosis [48–51]. Taken together, UVA-1
irradiation acts symptomatically by elimination of the in-
ﬂammatory lymphocytic inﬁltrate.
3. Photochemotherapy
Photochemotherapy terms the combination of psoralens
with UVA (PUVA) [52]. Psoralens (8-methoxypsoralen, 8-
MOP) can be applied orally (systemic PUVA) or topically
(bath- or cream-PUVA). Systemic PUVA has proven to be
eﬀective in severe atopic eczema, but relatively large numbers
of exposures had to be given [53–59]. In several patients who
did not continue topical application of corticosteroids, a re-
bound phenomenon occurred after termination of PUVA.
PUVA has been used in dermatology for over 30 years and
long-term safety data are available mostly for psoriatic pa-
tients. In psoriasis, long-term systemic PUVA is without
doubtassociatedwiththeincreasedrisktodevelopskinmali-
gnancies. After 25 years, more than 50% of the patients with
more than 400 treatments developed at least one squamous
cell carcinoma. Almost one-third of the patients exposed to
more than 200 treatments developed at least one basal cell
carcinoma [60–62] and it is also known that the risk of
malignant melanoma particularly in long-term therapy is
higher as well (>250 treatments) [63–65]. In atopic dermati-
tis, long-term safety data have not been investigated so far.
However, the potential risk must be weighed against the
potency of other therapies. In spite of long-term follow-
ups, which are essential in these patients, the performance of
long-term PUVA for atopic patients is strongly discouraged.
SystemicPUVAcanoccasionallycausesideeﬀectslikenausea
and vomiting, although this problem is much less common
with 5-methoxypsoralen, which is no longer available. It is
also less phototoxic, thus theoretically, 5-methoxypsoralen
should be favored. Unfortunately, it is not approved in most
countries and has been taken oﬀ the market recently. Other
disadvantages of oral psoralens are the relatively long pho-
tosensitivity (elimination not before 8 hours after ingestion)
and the necessity of eye protection. These problems can be
avoided, when applying psoralens topically [55, 66]. For
bath-PUVA, patients are bathing in warm water (20–30
minutes)thatcontainsapproximately0.5to1.0mgpsoralens
per liter. UVA exposure has to be performed immediately
after bathing. Alternatively, psoralen cream, usually a water-
in-oil ointment containing 0.0006% 8-methoxypsoralen, is
applied to a deﬁned area of lesional skin one hour before ir-
radiation, which has been shown to be very eﬀective in chro-
nic hand and foot dermatitis [66]. Therefore, cream PUVA
is a good option for atopic patients with dyshidrotic eczema,
in 70% complete remission has been reported. Cream PUVA
is superior to bath PUVA in clearing the lesions; the mois-
turizing of the skin may contribute to the beneﬁcial eﬀect
[55]. Furthermore, cream PUVA is easier in handling. The
mechanisms of PUVA are less well understood compared to
UVA or UVB treatment. PUVA is most eﬀective in psoriasis,
as UVA-induced DNA-psoralen photoadducts are presumed
to inhibit cell proliferation [67]. This was observed at psor-
alen concentrations and UVA doses, which do not aﬀect cell
viability [68] .H i g h e rd o s e sr e s u l t e di nb o t ha p o p t o s i sa n d
necrosis [68, 69]. The cell death of lymphocytes may be res-
ponsible for anti-inﬂammatory eﬀects and for therapeutic
eﬀects on lymphoproliferative diseases, like cutaneous T-cell
lymphoma. Therefore, PUVA aims to induce remissions of
skin diseases by repeated, controlled phototoxic reactions.
A recent publication states that PUVA reduces epidermal
hyperinnervation observed in atopic dermatitis, and there-
fore may target the development of pruritus [70]. PUVA will
be only recommended for severe atopic patients, in most
cases preference will be given to other phototherapeutic re-
gimens.
4. Extracorporeal Photopheresis (ECP)
Peripheral blood mononuclear cells are acquired from pa-
tients, exposed to UVA and psoralens (8-methoxypsoralen)
in an extracorporeal irradiation device and are reinfused
[71]. Alternatively, 8-methoxypsoralen may be taken orally
before treatment. Extracorporeal photopheresis was initially
developed for the treatment of cutaneous T-cell lymphoma,
in particular S´ ezary syndrome. However, photophoresis
proved to be also eﬀective in (auto)immune-mediated dis-
eases [72–75]. Due to its immunosuppressive/modulatory
capacity, photophoresis was applied experimentally in select-
ed patients with atopic dermatitis and in small studies and
turned out to be eﬀective in this indication when performed
in four-week intervals. However, ECP had to be combined
with topical corticosteroids to control disease activity [76].
Two-week intervals led to a signiﬁcant improvement of the
lesions, a decrease in the overall skin score as well as serum
ECP concentrations could be noted [77]. High levels of total
IgE turned out to be a predictor of negative outcome in ECP
[78]. Beyond, a signiﬁcant therapeutic eﬀect on the quality-
of-life improvement in patients who are refractory to con-
ventional forms of therapy [79]. Recently, long-term photo-
pheresis (>1 year) has been demonstrated to be eﬀective in
six patients with severe recalcitrant atopic dermatitis. All pa-
tients had a partial or complete remission [80]. In summary,
these ﬁndings suggest that extracorporeal phototherapy is
eﬀective in the treatment of atopic dermatitis in selectedJournal of Allergy 5
patients with severe disease, which are refractory to conven-
tional therapies. Nevertheless, ECP is expensive and time-
consuming and controlled randomized studies with suﬃ-
cient numbers of patients are still not available, so that this
therapy is only an option for selected patients.
5. CarcinogenicRisk
The induction of skin tumors after long-term PUVA (>200
treatments) is undoubted, whereas the role of UVB pho-
totherapy in human skin carcinogenesis is less clear. In a
murine study, the tumor outgrowth was enhanced by broad-
band UVB but not by narrowband UVB or UVA-1 [81]. In
mutant mice, UVB, but not UVA, was observed to induce
malignant melanoma [82]. However, UVA may also play a
role in the development of malignant melanoma [83]. The
long term skin cancer risk of narrowband UVB is thought to
be less than that of PUVA [84]. In spite of great clinical im-
portance, no data are available concerning the long-term risk
of developing skin cancer in children undergoing narrow-
band UVB. Furthermore, the underlying mechanisms of
UVB-induced biological actions are still not entirely clear.
There is recent evidence that UVB can also reach the upper
p a r t so ft h ed e r m i s ,h o w e v e r ,af o rl o n gt i m ei tw a ss u p p o s e d
that UVB can only act in the epidermis due to its lower pen-
etration compared with UVA. UVB induces apoptosis via
nuclearDNAdamageanddirectactivationofdeathreceptors
[85]andinpsoriaticlesionsitwasshownthatthetherapeutic
eﬀect of narrowband UVB is associated with the induction
of apoptosis of T lymphocytes [86]. The same eﬀect may be
relevant in atopic dermatitis. UVB has an immunosuppress-
ingeﬀectbyinhibitingantigenpresentationandinducingthe
release of immunosuppressive cytokines. It preferentially
inhibits Th1 immune responses and is even able to skew im-
munereactionstowardsaTh2type.Onﬁrstsight,thiswould
not support a beneﬁcial eﬀect of UVB in atopic dermatitis,
since atopy in general is regarded as a Th2 driven disease. In
chronic atopic dermatitis there is, however, a shift towards
a Th1 reaction which also explains why it resembles much
more a delayed-type hypersensitivity response. At this stage,
theimmunosuppressioncausedbyUVBshouldbeofbeneﬁt.
Thismayexplainwhychronicatopiclesionshaveabetterres-
ponse to UVB than acute lesions. Atopic skin has an altered
bacterial skin ﬂora and expresses diﬀerent levels of antimi-
crobial peptides compared with healthy or psoriatic skin.
Narrowband UVB has a signiﬁcant inﬂuence on the expres-
sion of antimicrobial peptides, bacterial colonization of the
skin surface, and bacterial superantigens. This pathological
antimicrobial response could explain the disposition for bac-
terial infections in atopic skin. Narrowband UVB therapy is
abletoreduceskin surfacebacteria,superantigenproduction
and alter mRNA levels of antimicrobial peptides, which have
been shown to trigger atopic dermatitis disease activity [87,
88].
In conclusion, in view of its eﬃcacy, beneﬁt-risk proﬁle,
and costs, narrowband UVB should be considered as the
ﬁrst-line phototherapeutic option for moderately severe ato-
pic dermatitis [89]. However, more clinical trials are needed
to investigate central issues such as carcinogenicity and eﬀec-
tiveness in skin diseases other than psoriasis. Taken together,
narrowband UVB is a very useful additive therapy for atopic
patients, which signiﬁcantly reduces disease activity, extent
of disease, and pruritus.
6. Conclusions and Perspectives
Phototherapy is still one of the major therapeutic options in
atopic dermatitis and this will certainly also apply in the
future. New developments, like UV-free phototherapy or ex-
cimer laser treatment might broaden the indication for
phototherapy [90–92]. Nevertheless, even for conventional
regimes, much more clinical research is needed to conﬁrm
potential indications and determining when and how it
should be used. While the development of phototherapeutic
regimens was mostly empirical in the past, recent develop-
ments are based on the increase of our knowledge on the
pathogenesis of atopic dermatitis as well as in the molecular
mechanisms mediating the biological eﬀects of UV radiation
[48, 93, 94]. Despite that, compared for example to psoriasis,
atopic dermatitis does less reliably respond to phototherapy
in general. There are still a reasonable number of patients
who do not respond or even get worse under phototherapy.
This may be due to the fact that atopic dermatitis is a highly
complex disease in which numerous factors determine the
clinical outcome and the therapeutic response. It is impor-
tant, to identify criteria and parameters, which will deter-
mine whether the patients will respond to phototherapy and
in particular to which type of treatment. This will permit an
individually customized phototherapeutic regimen for each
patient.
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